A Cambridge biotech pioneer in gene-editing medicine has taken a former employee and two rival companies to federal court, accusing them of lifting proprietary research to build a competing treatment for a rare genetic liver and lung disease. Beam Therapeutics filed suit Friday against Chinese company YolTech Therapeutics, its co-founders, and Nasdaq-listed Serapha Bio, alleging that a scientist who once worked in Beam's labs quietly funneled trade secrets into a rival gene-editing program now backed by hundreds of millions of dollars in venture capital.
The lawsuit, filed Sept. 25 in the U.S. District Court for the District of Massachusetts under the federal Defend Trade Secrets Act, names YolTech co-founders Yuxuan “Jensen” Wu and Zi Jun “Emma” Wang as defendants alongside Serapha Bio, according to court filings tracked by PacerMonitor. As reported by The Boston Globe, Beam alleges that Wang, who worked at the company from March 2021 to January 2022, accessed Beam's electronic laboratory notebooks late at night and on weekends, then used that information to help start YolTech Therapeutics in China.
A Scientist's After-Hours Access
According to the Globe's reporting, Beam claims Wang reviewed dozens of records she had never opened before, spanning technical areas well outside her own formulation work. Court filings relayed by Endpoints News add texture to that claim: Wang was a formulation scientist rather than a medicinal chemist, yet in June 2022, five months after leaving Beam, she filed a Chinese patent application listing herself as sole inventor of roughly 60 novel lipid molecules. Beam describes BEAM-302 as a liver-targeting lipid-nanoparticle formulation.
YolTech was founded in July 2021, per the Globe's account, and Wang is identified as a YolTech executive in social media posts and conference biographies. Beam alleges that Wang brought knowledge gained at Beam into YolTech's AATD program.
Both Companies Deny Wrongdoing
Neither accused company has conceded any wrongdoing. Serapha Bio's Chief Corporate Affairs Officer Shiva Fritsche said the company “categorically refutes Beam's claims” and will vigorously defend itself, according to BioPharma Dive. Serapha Bio has not otherwise commented on the lawsuit, and Roderick Wong referred questions about the case to Serapha, per the Globe's reporting. RA Capital did not respond to the Globe's request for comment.
Billions Riding on a Rare Disease Race
The dispute centers on Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic condition at the heart of the competing programs. Beam is developing a one-and-done therapy using its base editing technology to correct a disease-causing mutation, and is already running an early-stage clinical trial. At the European Respiratory Society Congress on Sept. 8, Beam presented Phase 1/2 data for its lead candidate, BEAM-302, showing durable gene correction and sustained functional protein production in patients for up to 18 months, per a company release on GlobeNewswire. The company dosed its first patient in a global pivotal trial in July as it pursues accelerated FDA approval.
YolTech and Serapha have moved fast to close the gap. In June, Serapha Bio licensed ex-Greater China rights to YolTech's lead AATD program, SERP-01, in exchange for upfront cash and a minority equity stake, leaving YolTech eligible for more than $2 billion in potential milestone payments plus tiered royalties, according to The Pharma Letter. That same month, RA Capital and RTW Investments launched Serapha Bio to develop a competing base-editing treatment for AATD, leading a $138 million investment, and the company announced another $92 million through a proposed all-stock reverse merger with San Diego-based Boundless Bio, which had halted its own lead oncology drug over low oral bioavailability. The planned combined company was to trade on Nasdaq under the ticker AATD. Before Beam's lawsuit, SERP-01 was expected to enter a Phase 2/3 trial later in 2026 or early 2027 and had Orphan Drug and Regenerative Medicine Advanced Therapy designations, according to Seeking Alpha — regulatory footing that puts the challenger closer behind Beam's clinical lead than the older biotech might like.
The case adds a legal front to a scientific rivalry that has been building for months, as two well-funded programs race toward a disease with no cure and a patient population waiting on either side of the Pacific for an answer.
